4.7 Article

Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study

Journal

BLOOD
Volume 119, Issue 12, Pages 2935-2942

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-04-349688

Keywords

-

Categories

Ask authors/readers for more resources

We investigated prospectively factors influencing the safety of hematopoietic stem cell (HSC) collection in 453 pediatric donors. The children in the study donated either BM or peripheral blood stem cells (PBSCs) according to center policy. A large variability in approach to donor issues was observed between the participating centers. Significant differences were observed between BM and PBSC donors regarding pain, blood allotransfusion, duration of hospital stay, and iron supplementation; however, differences between the groups undergoing BM vs PBSC donation preclude direct risk comparisons between the 2 procedures. The most common adverse event was pain, reported mainly by older children after BM harvest, but also observed after central venous catheter (CVC) placement for PBSC collection. With regard to severe adverse events, one patient (0.7%) developed a pneumothorax with hydrothorax after CVC placement for PBSC collection. The risk of allotransfusion after BM harvest was associated with a donor age of < 4 years and a BM harvest volume of > 20 mL/kg. Children < 4 years were at higher risk than older children for allotransfusion after BM harvest and there was a higher risk of complications from CVC placement before apheresis. We conclude that PBSC and BM collection are safe procedures in children. (Blood. 2012;119(12):2935-2942)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Transplantation

Successful Second Unrelated Donor Hematopoietic Stem Cell Transplant in a Patient With Dyskeratosis Congenital After First Graft Rejection

Stefano Giardino, Maura Faraci, Edoardo Lanino, Giuseppe Morreale, Paola Terranova, Elena Palmisani, Carlo Dufour, Maurizio Miano

Summary: Dyskeratosis congenita is a rare congenital telomeropathy with various clinical manifestations including cutaneous and nail dystrophy, oral leukoplakia, and bone marrow failure. The only curative treatment is allogeneic hematopoietic stem cell transplant, but outcomes are generally poor due to complications such as organ toxicities and graft-versus-host disease. This case report highlights a successful long-term outcome of a dyskeratosis congenita patient who underwent two consecutive transplants with fludarabine-based reduced intensity conditioning regimen. It emphasizes the high risk of transplant-related morbidity in dyskeratosis congenita and suggests the use of more effective prophylaxis schedules to reduce graft-versus-host disease.

EXPERIMENTAL AND CLINICAL TRANSPLANTATION (2023)

Article Biophysics

Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT

Jan Styczynski, Gloria Tridello, Linda Koster, Nina Knelange, Lotus Wendel, Anja van Biezen, Steffie van der Werf, Malgorzata Mikulska, Lidia Gil, Catherine Cordonnier, Per Ljungman, Diana Averbuch, Simone Cesaro, Helen Baldomero, Christian Chabannon, Selim Corbacioglu, Harry Dolstra, Bertram Glass, Raffaella Greco, Nicolaus Kroeger, Regis Peffault de Latour, Mohamad Mohty, Benedicte Neven, Zinaida Peric, John A. Snowden, Anna Sureda, Ibrahim Yakoub-Agha, Rafael de la Camara

Summary: This study analyzed the incidence and specific causes of death in HCT patients, focusing on infectious deaths. The results showed a decrease in mortality from infections in early phases but an increase in mortality from bacterial infections in the late phase.

BONE MARROW TRANSPLANTATION (2023)

Review Biotechnology & Applied Microbiology

Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation

Agata Marjanska, Jan Styczynski

Summary: Post-transplant lymphoproliferative disorders (PTLD) are a diverse group of diseases caused by uncontrolled proliferation of lymphoid or plasmacytic cells resulting from T-cell immunosuppression after transplantation. These are mainly caused by latent Epstein-Barr virus (EBV), and the risk of EBV recurrence depends on the level of immune system incompetency.

EXPERT OPINION ON BIOLOGICAL THERAPY (2023)

Article Oncology

Infection With Saprochaete Clavata in Children After Hematopoietic Cell Transplantation

Tomasz Styczynski, Jagoda Sadlok, Monika Richert-Przygonska, Robert Debski, Patrycja Zalas-Wiecek, Krzysztof Czyzewski, Jan Styczynski

Summary: This paper reports two cases of pediatric patients with invasive fungal disease caused by Saprochaete clavata after allogeneic hematopoietic cell transplantation, and summarizes the literature data on this infection. With quick diagnosis and treatment, the outcome of therapy was successful.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2023)

Article Oncology

Barriers and facilitators to implementation of the interoperable Survivorship Passport (SurPass) v2.0 in 6 European countries: a PanCareSurPass online survey study

Selina van den Oever, Ismay A. E. de Beijer, Leontien C. M. Kremer, Marie Alfes, Julia Balaguer, Edit Bardi, Adela Canete Nieto, Giorgio Cangioli, Eliana Charalambous, Catherine Chronaki, Tiago Costa, Alexander Degelsegger, Vanessa Duester, Anna-Liesa Filbert, Desiree Grabow, Gerald Gredinger, Hannah Gsell, Riccardo Haupt, Maria van Helvoirt, Ruth Ladenstein, Thorsten Langer, Anja Laschkolnig, Monica Muraca, Jelena Rascon, Guenter Schreier, Zuzana Tomasikova, Maria Teresa Tormo, Justas Trinkunas, Jessica Trollip, Kathrin Trunner, Anne Uyttebroeck, Helena J. H. van der Pal, Saskia M. F. Pluijm

Summary: This study aimed to identify barriers and facilitators to the implementation of the Survivorship Passport v2.0 (SurPass v2.0) in order to improve and ensure its effective application in clinical care. The main barriers identified included a lack of time and resources, gaps in knowledge concerning ethical and legal issues, and a potential increase in health-related anxiety in cancer survivors upon receiving a SurPass. Main facilitators included institutions' access to electronic medical records and previous experience with SurPass or similar tools.

JOURNAL OF CANCER SURVIVORSHIP (2023)

Review Medicine, General & Internal

The Development of New Agents for Post-Hematopoietic Stem Cell Transplantation Non-Infectious Complications in Children

Uri Ilan, Erica Brivio, Mattia Algeri, Adriana Balduzzi, Marta Gonzalez-Vincent, Franco Locatelli, Christian Michel Zwaan, Andre Baruchel, Caroline Lindemans, Francisco Bautista

Summary: Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for malignant diseases and some non-cancerous conditions, but it comes with high risks of complications. In recent years, there have been advancements in treatment options and prevention strategies for post-HSCT complications, with a focus on pediatric patients. This article reviews the latest developments and clinical trials for non-infectious complications.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Biophysics

Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT: survey of Infectious Diseases Working Party EBMT

Jan Styczynski, Gloria Tridello, Lotus Wendel, Nina Knelange, Simone Cesaro, Lidia Gil, Per Ljungman, Malgorzata Mikulska, Dina Averbuch, Rafael de la Camara

Summary: The aim of this study was to examine the current approach to EBV-driven post-transplant complications in EBMT transplant centers. The study found that most centers conduct routine serology testing before HCT, while some also routinely test for pretransplant EBV-DNA. Monitoring for EBV infection is feasible in almost all centers, with some using standardized PCR. Regular post-HCT monitoring is performed in the majority of centers. Prophylaxis with rituximab is used in a small percentage of centers. The prevalence of csEBV-DNA-emia was 7.4%, with higher rates in children. The frequency of EBV-PTLD was 1.6%, with higher rates in children. Rituximab and reduction of immunosuppressive therapy were the first-line treatments for EBV-driven complications. The failure rate of first-line preemptive treatment was 12.0%. EBV-specific T-lymphocytes were available in a portion of centers. Experimental therapies were given to patients with resistant/refractory PTLD. Overall, the prevalence of EBV-DNA-emia and EBV-PTLD decreased in comparison to historical data.

BONE MARROW TRANSPLANTATION (2023)

Letter Biophysics

Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT

Giorgia Battipaglia, Jarl E. Mooyaart, Ralf Meyer, Mohamad Mohty, Alicja Sadowska-Klasa, Oleg Goloshchapov, Franco Locatelli, Jan Styczynski, Jiri Pavlu, Jaroslaw Dybko, Gleb Bronin, Urpu Salmenniemi, Pavel Jindra, Jorinde D. Hoogenboom, Jurgen Kuball, Annalisa Ruggeri, Florent Malard

BONE MARROW TRANSPLANTATION (2023)

Article Oncology

Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Arend V. Stackelberg, Katja Jaeschke, Etienne Jousseaume, Corinna Templin, Ulli Jeratsch, Daniela Kosmides, Ingo Steffen, Nicola Goekbuget, Christina Peters

Summary: This study compared the efficacy of tisagenlecleucel with standard of care in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia. The results showed favorable outcomes for tisagenlecleucel in all examined endpoints, with statistically significant improvements in survival rates and overall response rate.

LEUKEMIA (2023)

Article Pharmacology & Pharmacy

A New Paclitaxel Formulation Based on Secretome Isolated from Mesenchymal Stem Cells Shows a Significant Cytotoxic Effect on Osteosarcoma Cell Lines

Alessia Giovanna Santa Banche Niclot, Elena Marini, Ivana Ferrero, Francesco Barbero, Elena Rosso, Ivana Fenoglio, Alessandro Barge, Augusto Pessina, Valentina Cocce, Francesca Paino, Katia Mareschi, Franca Fagioli

Summary: This study demonstrated that the conditioned medium isolated from MSCs loaded with PTX exhibited strong cytotoxic effects on OS cell lines. Additionally, the presence of nanoparticles with a size similar to extracellular vesicles and minimal doses of PTX were detected in the secretome.

PHARMACEUTICS (2023)

Article Psychology, Multidisciplinary

Neurocognitive and Psychological Outcomes among Children and Adolescents with Brain Tumors: Development of an Observational and Longitudinal Prospective Study Protocol

Giulia Zucchetti, Giorgia Gamberini, Sabrina Ciappina, Celeste Cagnazzo, Federica Ricci, Stefano Vallero, Paola Quarello, Paola Peretta, Franca Fagioli

Summary: This study aims to describe an innovative prospective observational study protocol for evaluating and monitoring the neuropsychological outcomes of children and adolescents affected by brain tumors. It involves assessing patients at three different time points using standardized neuropsychological tests, allowing clinicians to provide appropriate rehabilitation and educational programs from the early stages.

BEHAVIORAL SCIENCES (2023)

Article Hematology

Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

Brian D. Friend, Larisa Broglie, Brent R. Logan, Saurabh Chhabra, Caitrin Bupp, Gary Schiller, Amer Beitinjaneh, Miguel Angel Diaz Perez, Gregory M. T. Guilcher, Hasan Hashem, Gerhard C. Hildebrandt, Maxwell M. Krem, Hillard M. Lazarus, Taiga Nishihori, Roomi Nusrat, Seth J. Rotz, Baldeep Wirk, Matthew Wieduwilt, Marcelo Pasquini, Bipin N. Savani, Edward A. Stadtmauer, Mohamed L. Sorror, Monica S. Thakar

Summary: This study evaluated and developed new risk scoring tools for pediatric and young adult patients by expanding the definitions of Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI). The expanded ymHCT-CI and simplified ymHCT-CI, with broader definitions, were found to be more relevant in assessing the risk of non-relapse mortality in these patient populations. Further prospective studies are needed to validate the use of these novel comorbidity indexes in younger patients.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Pediatric Hematopoietic Stem Cell Transplantation: Challenges in Small European Countries

Jelena Rascon, Ramune Vaisnore, Ramune Pasauliene, Zanna Kovalova, Audrone Jakaitiene, Goda Vaitkeviciene

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Pediatrics

No Child Should Be Left Behind by COVID-19: A Report about the COVID-19 Pandemic Experience in Children and Adolescents with Acute or Chronic Disease Treated at a Pediatric Referral Hospital in Italy

Giulia Zucchetti, Sabrina Ciappina, Cristiana Risso, Alice Malabaila, Sara Racalbuto, Elena Longo, Margherita Dionisi Vici, Marina Bertolotti, Paola Quarello, Franca Fagioli

Summary: This study investigated the feelings of children and adolescents with acute or chronic illness towards the COVID-19 pandemic in Italy, and compared their experiences with children without illness. The results showed that participants, regardless of their health condition, felt fear of the virus and potential infection for themselves and their families, but experienced less interference with daily functioning. The fragile group demonstrated greater resilience towards the pandemic situation compared to the low-risk group, and some differences were found within the fragile group based on the type of illness.

PEDIATRIC REPORTS (2023)

Article Pediatrics

Prechemotherapy Transperitoneal Robotic-Assisted Partial Nephrectomy (RAPN) for a Wilms Tumor: Surgical and Oncological Outcomes in a Four-Year-Old Patient

Marcello Della Corte, Elisa Cerchia, Marco Oderda, Paola Quarello, Franca Fagioli, Paolo Gontero, Simona Gerocarni Nappo

Summary: This case report presents a prechemotherapy transperitoneal robot-assisted partial nephrectomy (RAPN) for a unilateral, non-syndromic Wilms tumor in a child. The patient showed no tumor recurrence during a 28-month follow-up period.

PEDIATRIC REPORTS (2023)

No Data Available